KR101940338B1 - Pim 키나제 억제제로서의 트라이아졸로피리딘 화합물 - Google Patents

Pim 키나제 억제제로서의 트라이아졸로피리딘 화합물 Download PDF

Info

Publication number
KR101940338B1
KR101940338B1 KR1020137025297A KR20137025297A KR101940338B1 KR 101940338 B1 KR101940338 B1 KR 101940338B1 KR 1020137025297 A KR1020137025297 A KR 1020137025297A KR 20137025297 A KR20137025297 A KR 20137025297A KR 101940338 B1 KR101940338 B1 KR 101940338B1
Authority
KR
South Korea
Prior art keywords
pyridin
triazolo
pyrrolidin
amine
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020137025297A
Other languages
English (en)
Korean (ko)
Other versions
KR20140021577A (ko
Inventor
제임스 에프 블레이크
로버트 커크 딜라일
리사 에이. 드 미스
제임스 엠. 그래이엄
이반 르 위루
마이클 라이온
존 이. 로빈슨
엘리 엠. 월래스
빈 왕
뤼 수
Original Assignee
어레이 바이오파마 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 어레이 바이오파마 인크. filed Critical 어레이 바이오파마 인크.
Publication of KR20140021577A publication Critical patent/KR20140021577A/ko
Application granted granted Critical
Publication of KR101940338B1 publication Critical patent/KR101940338B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020137025297A 2011-02-25 2012-02-24 Pim 키나제 억제제로서의 트라이아졸로피리딘 화합물 Expired - Fee Related KR101940338B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161446902P 2011-02-25 2011-02-25
US61/446,902 2011-02-25
PCT/US2012/026572 WO2012154274A1 (en) 2011-02-25 2012-02-24 Triazolopyridine compounds as pim kinase inhibitors

Publications (2)

Publication Number Publication Date
KR20140021577A KR20140021577A (ko) 2014-02-20
KR101940338B1 true KR101940338B1 (ko) 2019-01-18

Family

ID=46000320

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137025297A Expired - Fee Related KR101940338B1 (ko) 2011-02-25 2012-02-24 Pim 키나제 억제제로서의 트라이아졸로피리딘 화합물

Country Status (32)

Country Link
US (1) US8889704B2 (https=)
EP (1) EP2678329B1 (https=)
JP (2) JP6039585B2 (https=)
KR (1) KR101940338B1 (https=)
CN (1) CN103492377B (https=)
AR (1) AR085489A1 (https=)
AU (1) AU2012254082B2 (https=)
BR (1) BR112013021675A2 (https=)
CA (1) CA2828269C (https=)
CL (1) CL2013002446A1 (https=)
CO (1) CO6771441A2 (https=)
CR (1) CR20130460A (https=)
CY (1) CY1117197T1 (https=)
DK (1) DK2678329T3 (https=)
ES (1) ES2563152T3 (https=)
HR (1) HRP20160134T1 (https=)
HU (1) HUE027675T2 (https=)
IL (1) IL228108A (https=)
ME (1) ME02365B (https=)
MX (1) MX339899B (https=)
PH (1) PH12013501754A1 (https=)
PL (1) PL2678329T3 (https=)
RS (1) RS54586B1 (https=)
RU (1) RU2598846C2 (https=)
SG (1) SG192944A1 (https=)
SI (1) SI2678329T1 (https=)
SM (1) SMT201600052B (https=)
TW (1) TWI529170B (https=)
UA (1) UA111075C2 (https=)
UY (1) UY33924A (https=)
WO (1) WO2012154274A1 (https=)
ZA (1) ZA201306997B (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3812387A1 (en) 2011-07-21 2021-04-28 Sumitomo Dainippon Pharma Oncology, Inc. Heterocyclic protein kinase inhibitors
RU2014145806A (ru) * 2012-04-25 2016-06-10 Ф. Хоффманн-Ля Рош Аг Способы производства (3,4-дихлорфенил)-((s)-3-пропил-пирролидин-3-ил)-метанонгидрохлорида
ES2649156T3 (es) 2013-01-14 2018-01-10 Incyte Holdings Corporation Compuestos bicíclicos de carboxamida aromática útiles como inhibidores de quinasas Pim
PE20191245A1 (es) 2013-01-15 2019-09-18 Incyte Holdings Corp Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim
EA201690458A1 (ru) 2013-08-23 2016-07-29 Инсайт Корпорейшн Фуро- и тиенопиридинкарбоксамиды, используемые в качестве ингибиторов pim-киназы
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
TWI734699B (zh) 2015-09-09 2021-08-01 美商英塞特公司 Ｐｉｍ激酶抑制劑之鹽
US9920032B2 (en) 2015-10-02 2018-03-20 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
EP3464270B1 (en) * 2016-05-24 2022-02-23 Genentech, Inc. Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
JP2021521170A (ja) 2018-04-13 2021-08-26 スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド 骨髄増殖性新生物およびがんに関連する線維症の処置のためのｐｉｍキナーゼ阻害剤
US20220363667A1 (en) 2018-07-17 2022-11-17 Nippon Chemiphar Co., Ltd. T-type calcium channel blocker
CN108912032A (zh) * 2018-08-13 2018-11-30 南通大学 一种（3s，4r）-4-甲基吡咯烷-3-基氨基甲醇叔丁酯盐酸盐的化学合成方法
CN109053526A (zh) * 2018-08-13 2018-12-21 南通大学 一种（3r，4s）-4-甲基吡咯烷-3-基氨基甲酸叔丁酯盐酸盐的化学合成方法
WO2020157709A1 (en) 2019-02-01 2020-08-06 Pfizer Inc. Combination of a cdk inhibitor and a pim inhibitor
KR20260008165A (ko) 2019-02-12 2026-01-15 스미토모 파마 아메리카, 인크. 헤테로시클릭 단백질 키나제 억제제를 포함하는 제제
EP3929185A4 (en) * 2019-02-19 2023-02-15 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. NITROGEN CONDENSED CYCLIC COMPOUND, METHOD OF PRODUCTION THEREOF AND USE THEREOF
AU2020250468A1 (en) 2019-03-29 2021-11-04 Kinki University Use of T-type calcium channel blocker for treating pruritus
CN111171023B (zh) * 2020-01-10 2021-12-21 中国药科大学 一种具有Pim1抑制活性的化合物及其制备方法与医药用途
CN120302975A (zh) 2022-10-31 2025-07-11 住友制药美国公司 治疗骨髓增生性肿瘤的pim1抑制剂

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010022076A1 (en) 2008-08-19 2010-02-25 Array Biopharma Inc. Triazolopyridine compounds as pim kinase inhibitors
WO2010022081A1 (en) 2008-08-19 2010-02-25 Array Biopharma Inc. Triazolopyridine compounds as pim kinase inhibitors

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2388593A1 (en) 1999-11-12 2001-05-17 Neurogen Corporation Bicyclic and tricyclic heteroaromatic compounds
UA75055C2 (uk) * 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
CN1173975C (zh) 2000-04-27 2004-11-03 山之内制药株式会社 咪唑并吡啶衍生物
DE10038019A1 (de) 2000-08-04 2002-02-14 Bayer Ag Substituierte Triazolopyrid(az)ine
HUP0303415A2 (hu) 2001-03-09 2004-01-28 Pfizer Products Inc. Triazolopiridinek, mint gyulladásgátló anyagok és ezeket tartalmazó gyógyszerkészítmények
US7227006B2 (en) 2002-01-19 2007-06-05 Sanofi-Aventis Deutschland Gmbh PIM-3 kinase as a target for type 2 diabetes mellitus
WO2004058769A2 (en) 2002-12-18 2004-07-15 Vertex Pharmaceuticals Incorporated Triazolopyridazines as protein kinases inhibitors
DE60326646D1 (de) 2002-12-18 2009-04-23 Vertex Pharma Benzisoxazolderivate, die sich als inhibitoren von proteinkinasen eigen
WO2005028624A2 (en) 2003-09-15 2005-03-31 Plexxikon, Inc. Molecular scaffolds for kinase ligand development
US20050256309A1 (en) 2004-05-12 2005-11-17 Altenbach Robert J Tri-and bi-cyclic heteroaryl histamine-3 receptor ligands
BRPI0514391A (pt) 2004-08-18 2008-06-10 Pharmacia & Upjohn Co Llc compostos de triazolopiridina para o tratamento de inflamação
EP1828184B1 (en) 2004-12-01 2009-09-16 Merck Serono SA [1,2,4]triazolo[4,3-a]pyridine derivatives for the treatment of hyperproliferative diseases
WO2007044724A2 (en) 2005-10-06 2007-04-19 Exelixis, Inc. Aminopyrimidine, aminopyridine and aniline derivatives inhibitors of pim-i and/or pim-3
EP1978966A4 (en) 2006-01-23 2010-11-10 Amira Pharmaceuticals Inc TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE
EP2029605A1 (en) 2006-06-06 2009-03-04 Schering Corporation Imidazopyrazines as protein kinase inhibitors
WO2008058126A2 (en) 2006-11-06 2008-05-15 Supergen, Inc. Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
WO2008082839A2 (en) 2006-12-29 2008-07-10 Abbott Laboratories Pim kinase inhibitors as cancer chemotherapeutics
WO2008108958A2 (en) * 2007-03-02 2008-09-12 Schering Corporation Benzimidazole derivatives and methods of use thereof
JP2010522765A (ja) * 2007-03-28 2010-07-08 アレイ バイオファーマ、インコーポレイテッド 受容体チロシンキナーゼとしてのイミダゾ［１，２−ａ］ピリジン化合物
NZ580327A (en) * 2007-04-03 2012-02-24 Array Biopharma Inc IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS
CL2009001152A1 (es) 2008-05-13 2009-10-16 Array Biopharma Inc Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa.
WO2010039825A2 (en) * 2008-10-01 2010-04-08 Array Biopharma Inc. IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS
AU2010229142A1 (en) * 2009-03-23 2011-10-13 Merck Sharp & Dohme Corp. P2X3, receptor antagonists for treatment of pain

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010022076A1 (en) 2008-08-19 2010-02-25 Array Biopharma Inc. Triazolopyridine compounds as pim kinase inhibitors
WO2010022081A1 (en) 2008-08-19 2010-02-25 Array Biopharma Inc. Triazolopyridine compounds as pim kinase inhibitors

Also Published As

Publication number Publication date
TW201245193A (en) 2012-11-16
CO6771441A2 (es) 2013-10-15
JP2016106118A (ja) 2016-06-16
CN103492377A (zh) 2014-01-01
EP2678329B1 (en) 2015-11-18
HUE027675T2 (en) 2016-11-28
HRP20160134T1 (hr) 2016-04-08
TWI529170B (zh) 2016-04-11
CL2013002446A1 (es) 2014-04-11
RU2598846C2 (ru) 2016-09-27
JP2014509322A (ja) 2014-04-17
EP2678329A1 (en) 2014-01-01
US20140005213A1 (en) 2014-01-02
IL228108A (en) 2017-07-31
ME02365B (me) 2016-06-20
SMT201600052B (it) 2016-04-29
ZA201306997B (en) 2015-05-27
CN103492377B (zh) 2016-04-20
UA111075C2 (uk) 2016-03-25
US8889704B2 (en) 2014-11-18
WO2012154274A1 (en) 2012-11-15
IL228108A0 (en) 2013-09-30
CY1117197T1 (el) 2017-04-05
DK2678329T3 (da) 2016-02-22
AR085489A1 (es) 2013-10-09
HK1190714A1 (zh) 2014-07-11
SI2678329T1 (sl) 2016-05-31
ES2563152T3 (es) 2016-03-11
PL2678329T3 (pl) 2016-06-30
SG192944A1 (en) 2013-09-30
CA2828269C (en) 2019-01-15
CA2828269A1 (en) 2012-11-15
AU2012254082A1 (en) 2013-09-26
RS54586B1 (sr) 2016-08-31
JP6039585B2 (ja) 2016-12-07
BR112013021675A2 (pt) 2016-11-01
AU2012254082B2 (en) 2016-12-08
UY33924A (es) 2013-09-30
KR20140021577A (ko) 2014-02-20
MX2013009820A (es) 2014-09-01
CR20130460A (es) 2013-10-16
NZ615300A (en) 2014-12-24
MX339899B (es) 2016-06-16
RU2013143292A (ru) 2015-04-10
PH12013501754A1 (en) 2013-10-14

Similar Documents

Publication Publication Date Title
KR101940338B1 (ko) Pim 키나제 억제제로서의 트라이아졸로피리딘 화합물
EP2334677B1 (en) Triazolopyridine compounds as pim kinase inhibitors
US10730889B2 (en) Amido spirocyclic amide and sulfonamide derivatives
KR102311840B1 (ko) Pim 키나제 저해제로서 유용한 티아졸카복스아마이드 및 피리딘카복스아마이드 화합물
JP2010522765A (ja) 受容体チロシンキナーゼとしてのイミダゾ［１，２−ａ］ピリジン化合物
TW202241418A (zh) 作為cd38之抑制劑的喹啉及氮雜喹啉
US8987251B2 (en) Triazolopyridine compounds as PIM kinase inhibitors
NZ615300B2 (en) Triazolopyridine compounds as pim kinase inhibitors
HK1190714B (en) Triazolopyridine compounds as pim kinase inhibitors

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

X091 Application refused [patent]
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20220115

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20220115